Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
Conditions: Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-Negati ve Breast Carcinoma Interventions: Drug: Capecitabine; Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab Sponsors: Northwestern University; Merck Sharp & Dohme Corp.; National Cancer Institute (NCI) Not yet recruiting - verified February 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | HER2 | Hormone Refractory Prostate Cancer | Hormones | Xeloda